Navigation Links
Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
Date:9/5/2007

FREEPORT, N.Y., Sept. 5 /PRNewswire/ -- AGI Dermatics, the bio- pharmaceutical laboratory that pioneered DNA research for skincare, announced today that U.S. Food & Drug Administration (FDA) has granted Fast Track designation for Dimericine (T4N5) for treatment of solar and ultraviolet photosensitivity in patients with Xeroderma Pigmentosum (XP). Dimericine, also known as T4N5 Liposome Lotion, is a topical drug developed by AGI currently in clinical trials for treating XP patients with skin cancers and pre-cancers.

"Dimericine is the result of decades of research into DNA repair and its potential to prevent skin cancer and photodamage caused by UV radiation," said Daniel Yarosh, Ph.D., President and CEO of AGI Dermatics. "We are optimistic that this Fast Track designation will accelerate our efforts to bring to market a treatment option for the thousands of people who suffer from the life-threatening disease XP."

Xeroderma pigmentosum, or XP, is a rare genetic disorder that blocks the body's natural ability to repair DNA damage caused by ultraviolet (UV) light. Minimal exposure to UV light in XP patients results in persistent DNA damage and causes severe sunburn, blistering, irregular dark spots and a 1000-fold increased risk of skin cancer. People with severe XP often need to avoid sunlight completely. Half of these patients develop skin cancers by the age of 8 and their life expectancy is shortened by 30 years.

Fast Track programs are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life- threatening conditions and that demonstrate the potential to address unmet medical needs. It grants accelerated review for all steps of the process, including the applications related to clinical developments and may reduce the time required to bring the drug to market. With this designation, the FDA has acknowledged XP as a serious or life threatening disease and has also determined there is no drug currently marketed for treatment of XP.

About AGI Dermatics

AGI Dermatics is the bio-pharmaceutical laboratory that has led the research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell-signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. http://www.agiderm.com


'/>"/>
SOURCE AGI Dermatics
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
5. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
8. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
9. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
10. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
11. Point of Care Strep Tests Speed Treatment, Lower Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun ... NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is ... is geared towards children of all ages; it is a non-competitive, non-timed event, which ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
(Date:10/12/2017)... ... 12, 2017 , ... In the United States, single-family home ... states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is ... low property-tax rates, which contributes to the relatively lower cost of living in ...
Breaking Medicine News(10 mins):